Introduction: Concomitant use of drugs in the same or different indications can sometimes lead to undesirable interactions. The prevalence of drug interactions is high in cancer patients. In this study, we aimed to determine the frequency and clinical severity of drug interactions in outpatient lung cancer patients. Methods: The drugs used, kidney and liver blood analysis results of 160 outpatient lung cancer patients over the age of 18 years who received chemotherapy between October 2020 and July 2021 were evaluated. The Lexi-Interact online database was used to identify the types of clinically significant drug interactions, frequently interacting drugs, and clinical outcomes predicted by the databases. Results: The average number of drugs per patient was 4.2 ± 2.3. It was determined that there was a relationship between multidrug use and comorbidity, and the number of drugs used increased as the number of diagnoses increased. A relationship was also found between potential drug-drug interactions (pDDIs), which we observed in 52.5% of the patients, and the number of drugs used and age. The most common clinically significant C- (36.9%), D- (16.9%), and X- (10.6%) type pDDIs were detected between conventional paclitaxel-hydrochlorothiazide, conventional paclitaxel-carboplatin, and ipratropium-tiotropium, respectively. Conclusions: The use of frequently interacting drugs in outpatient lung cancer patients can lead to pDDIs. In these patients, the application of therapy by observing the drug-drug interaction may improve the quality of life.

1.
Siegel
RL
,
Miller
KD
,
Fuchs
HE
,
Jemal
A
.
Cancer statistics, 2021
.
CA Cancer J Clin
.
2021
;
71
(
1
):
7
33
.
2.
Dingemans
AMC
,
Früh
M
,
Ardizzoni
A
,
Besse
B
,
Faivre-Finn
C
,
Hendriks
LE
, et al
.
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
.
Ann Oncol
.
2021
;
32
(
7
):
839
53
.
3.
Sogaard
M
,
W Thomsen
R
,
Bossen
KS
,
Henrik Toft Sørensen
H
,
Nørgaard
M
.
The impact of comorbidity on cancer survival: a review
.
Clin Epidemiol
.
2013
;
5
(
Suppl 1
):
3
29
.
4.
Jafarova Demirkapu
M
,
Pinar Kara
S
.
Potential drug-drug interactions in university hospital medical intensive Care unit patients in Turkey
.
Eur Rev Med Pharmacol Sci
.
2021
;
25
(
22
):
7108
14
.
5.
Sculier
JP
,
Botta
I
,
Bucalau
AM
,
Compagnie
M
,
Eskenazi
A
,
Fischler
R
, et al
.
Medical anticancer treatment of lung cancer associated with comorbidities: a review
.
Lung Cancer
.
2015
;
87
(
3
):
241
8
.
6.
Ismail
M
,
Khan
S
,
Khan
F
,
Noor
S
,
Sajid
H
,
Yar
S
, et al
.
Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy
.
BMC Cancer
.
2020
;
20
(
1
):
335
.
7.
Hines
LE
,
Murphy
JE
.
Potentially harmful drug-drug interactions in the elderly: a review
.
Am J Geriatr Pharmacother
.
2011
;
9
(
6
):
364
77
.
8.
Kunac
DL
,
Kennedy
J
,
Austin
N
,
Reith
D
.
Incidence, preventability, and impact of Adverse Drug Events (ADEs) and potential ADEs in hospitalized children in New Zealand: a prospective observational cohort study
.
Paediatr Drugs
.
2009
;
11
(
2
):
153
60
.
9.
UpToDate, Inc
. Lexi-interact. Available from: https://www.uptodate.com/drug-interactions/?source=responsive_home#di-druglist (accessed September 20, 2023).
10.
Scripture
CD
,
Figg
WD
.
Drug interactions in cancer therapy
.
Nat Rev Cancer
.
2006
;
6
(
7
):
546
58
.
11.
van Leeuwen
RW
,
Swart
EL
,
Boven
E
,
Boom
FA
,
Schuitenmaker
MG
,
Hugtenburg
JG
.
Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method
.
Ann Oncol
.
2011
;
22
(
10
):
2334
41
.
12.
Albayrak
A
,
Düzenli
T
,
Kayıkçıoğlu
E
.
Potential drug-drug interactions in patients with non-small cell lung cancer at a university hospital in Turkey
.
J Cancer Res Clin Oncol
.
2023
;
149
(
12
):
9621
7
.
13.
Occhipinti
M
,
Brambilla
M
,
Galli
G
,
Manglaviti
S
,
Prelaj
A
,
Ferrara
R
, et al
.
133P Drug-Drug Interactions (DDIs) in non-small cell lung cancer during chemotherapy-immunotherapy treatment
.
J Thorac Oncol
.
2021
;
16
(
4
):
S769
S770
.
14.
Riechelmann
RP
,
Tannock
IF
,
Wang
L
,
Saad
ED
,
Taback
NA
,
Krzyzanowska
MK
.
Potential drug interactions and duplicate prescriptions among cancer patients
.
J Natl Cancer Inst
.
2007
;
99
(
8
):
592
600
.
15.
Freeman
JS
,
Gross
B
.
Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review
.
Expert Rev Clin Pharmacol
.
2012
;
5
(
1
):
31
42
.
16.
Loadman
PM
,
Bibby
MC
.
Pharmacokinetic drug interactions with anticancer drugs
.
Clin Pharmacokinet
.
1994
;
26
(
6
):
486
500
.
17.
Riechelmann
RP
,
Del Giglio
A
.
Drug interactions in oncology: how common are they
.
Ann Oncol
.
2009
;
20
(
12
):
1907
12
.
18.
Dumbreck
S
,
Flynn
A
,
Nairn
M
,
Wilson
M
,
Treweek
S
,
Mercer
SW
, et al
.
Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines
.
BMJ
.
2015
;
350
:
h949
.
19.
Bellmunt
J
,
von der Maase
H
,
Mead
GM
,
Skoneczna
I
,
De Santis
M
,
Daugaard
G
, et al
.
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987
.
J Clin Oncol
.
2012
;
30
(
10
):
1107
13
.
20.
Huizing
MT
,
Giaccone
G
,
van Warmerdam
LJ
,
Rosing
H
,
Bakker
PJ
,
Vermorken
JB
, et al
.
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre
.
J Clin Oncol
.
1997
;
15
(
1
):
317
29
.
21.
Price
D
,
Sharma
A
,
Cerasoli
F
.
Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients
.
Expert Opin Drug Metab Toxicol
.
2009
;
5
(
4
):
417
24
.
22.
Keating
GM
.
Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia
.
Drugs
.
2015
;
75
(
2
):
207
17
.
23.
Cano-Mollinedo
M
,
Rodríguez Del Río
P
,
Sánchez-García
S
,
Escudero
C
,
Ibañez
MD
.
Serious adverse reaction to timolol eye drops in a 7-year-old boy with glaucoma and asthma
.
J Investig Allergol Clin Immunol
.
2016
;
26
(
6
):
379
81
.
You do not currently have access to this content.